ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Research Report 2026
Published Date: 2026-02-05
|
Report Code: QYRE-Auto-21J18270
Home | Market Reports | Health| Nutrition| Vitamins & Supplements
Global N Acetylglutamate Synthetase Deficiency NAGSD Market Research Report 2024
BUY CHAPTERS

Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Research Report 2026

Code: QYRE-Auto-21J18270
Report
2026-02-05
Pages:101
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Recordati Rare Diseases
Grand Pharmaceutical Group
Medunik
Acer Therapeutics
Sigmapharm Laboratories
Amgen Inc
Immedica
Sovereign Medical
Lee's Pharmaceuticals

N-Acetylglutamate Synthetase Deficiency (NAGSD) Market

The global N-Acetylglutamate Synthetase Deficiency (NAGSD) market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.
N-Acetylglutamate Synthase Deficiency (NAGS Deficiency) is a rare inherited metabolic disorder and a member of the urea cycle disorders (UCDs). The urea cycle converts toxic ammonia in the body into non-toxic urea, which is excreted from the body through the kidneys.
The North American market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The Asia-Pacific market for N-Acetylglutamate Synthetase Deficiency (NAGSD) is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.
The global market for N-Acetylglutamate Synthetase Deficiency (NAGSD) in Adults is estimated to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % from 2026 to 2032.
Major global companies of N-Acetylglutamate Synthetase Deficiency (NAGSD) include Recordati Rare Diseases, Grand Pharmaceutical Group, Sovereign Medical, Lee's Pharmaceuticals, Medunik, Acer Therapeutics, Sigmapharm Laboratories, Amgen, Immedica, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.
This report delivers a comprehensive overview of the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding N-Acetylglutamate Synthetase Deficiency (NAGSD). The N-Acetylglutamate Synthetase Deficiency (NAGSD) market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global N-Acetylglutamate Synthetase Deficiency (NAGSD) market comprehensively. Regional market sizes by Type, by Application, , and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist N-Acetylglutamate Synthetase Deficiency (NAGSD) manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation

Scope of N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Report

Report Metric Details
Report Name N-Acetylglutamate Synthetase Deficiency (NAGSD) Market
Segment by Type
  • Original Drug
  • Generic Drug
Segment by Application
  • Adults
  • Children
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Recordati Rare Diseases, Grand Pharmaceutical Group, Sovereign Medical, Lee's Pharmaceuticals, Medunik, Acer Therapeutics, Sigmapharm Laboratories, Amgen, Immedica
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
  • Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
  • Chapter 3: Provides a detailed view of the competitive landscape for N-Acetylglutamate Synthetase Deficiency (NAGSD) companies, covering revenue share, development plans, and mergers and acquisitions.
  • Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
  • Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
  • Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
  • Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
  • Chapter 12: Key findings and conclusions of the report.

FAQ for this report

Who are the main players in the N-Acetylglutamate Synthetase Deficiency (NAGSD) Market report?

Ans: The main players in the N-Acetylglutamate Synthetase Deficiency (NAGSD) Market are Recordati Rare Diseases, Grand Pharmaceutical Group, Sovereign Medical, Lee's Pharmaceuticals, Medunik, Acer Therapeutics, Sigmapharm Laboratories, Amgen, Immedica

What are the Application segmentation covered in the N-Acetylglutamate Synthetase Deficiency (NAGSD) Market report?

Ans: The Applications covered in the N-Acetylglutamate Synthetase Deficiency (NAGSD) Market report are Adults, Children

What are the Type segmentation covered in the N-Acetylglutamate Synthetase Deficiency (NAGSD) Market report?

Ans: The Types covered in the N-Acetylglutamate Synthetase Deficiency (NAGSD) Market report are Original Drug, Generic Drug

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Type: 2021 vs 2025 vs 2032
1.2.2 Original Drug
1.2.3 Generic Drug
1.3 Market by Application
1.3.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth by Application: 2021 vs 2025 vs 2032
1.3.2 Adults
1.3.3 Children
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Perspective (2021–2032)
2.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Growth Trends by Region
2.2.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region: 2021 vs 2025 vs 2032
2.2.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Historic Market Size by Region (2021–2026)
2.2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Region (2027–2032)
2.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Dynamics
2.3.1 N-Acetylglutamate Synthetase Deficiency (NAGSD) Industry Trends
2.3.2 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Drivers
2.3.3 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Challenges
2.3.4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Players by Revenue
3.1.1 Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Players by Revenue (2021–2026)
3.1.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Players (2021–2026)
3.2 Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
3.3 Global Key Players Ranking by N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue
3.4 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Concentration Ratio
3.4.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue in 2025
3.5 Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD) Head Offices and Areas Served
3.6 Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD), Products and Applications
3.7 Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD), Date of General Availability (GA)
3.8 Mergers and Acquisitions, Expansion Plans
4 N-Acetylglutamate Synthetase Deficiency (NAGSD) Breakdown Data by Type
4.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Historic Market Size by Type (2021–2026)
4.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Type (2027–2032)
5 N-Acetylglutamate Synthetase Deficiency (NAGSD) Breakdown Data by Application
5.1 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Historic Market Size by Application (2021–2026)
5.2 Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Application (2027–2032)
6 North America
6.1 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021–2032)
6.2 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 vs 2025 vs 2032
6.3 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021–2026)
6.4 North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027–2032)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021–2032)
7.2 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 vs 2025 vs 2032
7.3 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021–2026)
7.4 Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027–2032)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Ireland
8 Asia-Pacific
8.1 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021–2032)
8.2 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Region: 2021 vs 2025 vs 2032
8.3 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (2021–2026)
8.4 Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (2027–2032)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia & New Zealand
9 Latin America
9.1 Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021–2032)
9.2 Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 vs 2025 vs 2032
9.3 Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021–2026)
9.4 Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027–2032)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (2021–2032)
10.2 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Growth Rate by Country: 2021 vs 2025 vs 2032
10.3 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2021–2026)
10.4 Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (2027–2032)
10.5 Israel
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Recordati Rare Diseases
11.1.1 Recordati Rare Diseases Company Details
11.1.2 Recordati Rare Diseases Business Overview
11.1.3 Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.1.4 Recordati Rare Diseases Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.1.5 Recordati Rare Diseases Recent Development
11.2 Grand Pharmaceutical Group
11.2.1 Grand Pharmaceutical Group Company Details
11.2.2 Grand Pharmaceutical Group Business Overview
11.2.3 Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.2.4 Grand Pharmaceutical Group Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.2.5 Grand Pharmaceutical Group Recent Development
11.3 Sovereign Medical
11.3.1 Sovereign Medical Company Details
11.3.2 Sovereign Medical Business Overview
11.3.3 Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.3.4 Sovereign Medical Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.3.5 Sovereign Medical Recent Development
11.4 Lee's Pharmaceuticals
11.4.1 Lee's Pharmaceuticals Company Details
11.4.2 Lee's Pharmaceuticals Business Overview
11.4.3 Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.4.4 Lee's Pharmaceuticals Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.4.5 Lee's Pharmaceuticals Recent Development
11.5 Medunik
11.5.1 Medunik Company Details
11.5.2 Medunik Business Overview
11.5.3 Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.5.4 Medunik Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.5.5 Medunik Recent Development
11.6 Acer Therapeutics
11.6.1 Acer Therapeutics Company Details
11.6.2 Acer Therapeutics Business Overview
11.6.3 Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.6.4 Acer Therapeutics Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.6.5 Acer Therapeutics Recent Development
11.7 Sigmapharm Laboratories
11.7.1 Sigmapharm Laboratories Company Details
11.7.2 Sigmapharm Laboratories Business Overview
11.7.3 Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.7.4 Sigmapharm Laboratories Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.7.5 Sigmapharm Laboratories Recent Development
11.8 Amgen
11.8.1 Amgen Company Details
11.8.2 Amgen Business Overview
11.8.3 Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.8.4 Amgen Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.8.5 Amgen Recent Development
11.9 Immedica
11.9.1 Immedica Company Details
11.9.2 Immedica Business Overview
11.9.3 Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Introduction
11.9.4 Immedica Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
11.9.5 Immedica Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Recordati Rare Diseases
Grand Pharmaceutical Group
Medunik
Acer Therapeutics
Sigmapharm Laboratories
Amgen Inc
Immedica
Sovereign Medical
Lee's Pharmaceuticals
List of Tables
 Table 1. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Type (US$ Million): 2021 vs 2025 vs 2032
 Table 2. Key Players of Original Drug
 Table 3. Key Players of Generic Drug
 Table 4. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032
 Table 5. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 6. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (US$ Million), 2021–2026
 Table 7. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region (2021–2026)
 Table 8. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Region (US$ Million), 2027–2032
 Table 9. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region (2027–2032)
 Table 10. N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Trends
 Table 11. N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Drivers
 Table 12. N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Challenges
 Table 13. N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Restraints
 Table 14. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue by Players (US$ Million), 2021–2026
 Table 15. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Players (2021–2026)
 Table 16. Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Players by Tier (Tier 1, Tier 2, and Tier 3), based on N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue, 2025
 Table 17. Ranking of Global Top N-Acetylglutamate Synthetase Deficiency (NAGSD) Companies by Revenue (US$ Million) in 2025
 Table 18. Global 5 Largest Players Market Share by N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue (CR5 and HHI), 2021–2026
 Table 19. Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD), Headquarters and Area Served
 Table 20. Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD), Products and Applications
 Table 21. Global Key Players of N-Acetylglutamate Synthetase Deficiency (NAGSD), Date of General Availability (GA)
 Table 22. Mergers and Acquisitions, Expansion Plans
 Table 23. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Type (US$ Million), 2021–2026
 Table 24. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Type (2021–2026)
 Table 25. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Type (US$ Million), 2027–2032
 Table 26. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Type (2027–2032)
 Table 27. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Application (US$ Million), 2021–2026
 Table 28. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2021–2026)
 Table 29. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Forecasted Market Size by Application (US$ Million), 2027–2032
 Table 30. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue Market Share by Application (2027–2032)
 Table 31. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 32. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2021–2026
 Table 33. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2027–2032
 Table 34. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 35. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2021–2026
 Table 36. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2027–2032
 Table 37. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032
 Table 38. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (US$ Million), 2021–2026
 Table 39. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Region (US$ Million), 2027–2032
 Table 40. Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 41. Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2021–2026
 Table 42. Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2027–2032
 Table 43. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032
 Table 44. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2021–2026
 Table 45. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Country (US$ Million), 2027–2032
 Table 46. Recordati Rare Diseases Company Details
 Table 47. Recordati Rare Diseases Business Overview
 Table 48. Recordati Rare Diseases N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 49. Recordati Rare Diseases Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 50. Recordati Rare Diseases Recent Development
 Table 51. Grand Pharmaceutical Group Company Details
 Table 52. Grand Pharmaceutical Group Business Overview
 Table 53. Grand Pharmaceutical Group N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 54. Grand Pharmaceutical Group Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 55. Grand Pharmaceutical Group Recent Development
 Table 56. Sovereign Medical Company Details
 Table 57. Sovereign Medical Business Overview
 Table 58. Sovereign Medical N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 59. Sovereign Medical Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 60. Sovereign Medical Recent Development
 Table 61. Lee's Pharmaceuticals Company Details
 Table 62. Lee's Pharmaceuticals Business Overview
 Table 63. Lee's Pharmaceuticals N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 64. Lee's Pharmaceuticals Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 65. Lee's Pharmaceuticals Recent Development
 Table 66. Medunik Company Details
 Table 67. Medunik Business Overview
 Table 68. Medunik N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 69. Medunik Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 70. Medunik Recent Development
 Table 71. Acer Therapeutics Company Details
 Table 72. Acer Therapeutics Business Overview
 Table 73. Acer Therapeutics N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 74. Acer Therapeutics Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 75. Acer Therapeutics Recent Development
 Table 76. Sigmapharm Laboratories Company Details
 Table 77. Sigmapharm Laboratories Business Overview
 Table 78. Sigmapharm Laboratories N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 79. Sigmapharm Laboratories Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 80. Sigmapharm Laboratories Recent Development
 Table 81. Amgen Company Details
 Table 82. Amgen Business Overview
 Table 83. Amgen N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 84. Amgen Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 85. Amgen Recent Development
 Table 86. Immedica Company Details
 Table 87. Immedica Business Overview
 Table 88. Immedica N-Acetylglutamate Synthetase Deficiency (NAGSD) Product
 Table 89. Immedica Revenue in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (US$ Million), 2021–2026
 Table 90. Immedica Recent Development
 Table 91. Research Programs/Design for This Report
 Table 92. Key Data Information from Secondary Sources
 Table 93. Key Data Information from Primary Sources
 Table 94. Authors List of This Report


List of Figures
 Figure 1. N-Acetylglutamate Synthetase Deficiency (NAGSD) Picture
 Figure 2. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size Comparison by Type (US$ Million), 2021–2032
 Figure 3. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Type: 2025 vs 2032
 Figure 4. Original Drug Features
 Figure 5. Generic Drug Features
 Figure 6. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size by Application (US$ Million), 2021–2032
 Figure 7. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Application: 2025 vs 2032
 Figure 8. Adults Case Studies
 Figure 9. Children Case Studies
 Figure 10. N-Acetylglutamate Synthetase Deficiency (NAGSD) Report Years Considered
 Figure 11. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size (US$ Million), Year-over-Year: 2021–2032
 Figure 12. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size, (US$ Million), 2021 vs 2025 vs 2032
 Figure 13. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region: 2025 vs 2032
 Figure 14. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Players in 2025
 Figure 15. Global N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 16. The Top 10 and 5 Players Market Share by N-Acetylglutamate Synthetase Deficiency (NAGSD) Revenue in 2025
 Figure 17. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 18. North America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Country (2021–2032)
 Figure 19. United States N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 20. Canada N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 21. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 22. Europe N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Country (2021–2032)
 Figure 23. Germany N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 24. France N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 25. U.K. N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 26. Italy N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 27. Russia N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 28. Ireland N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 29. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 30. Asia-Pacific N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Region (2021–2032)
 Figure 31. China N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 32. Japan N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 33. South Korea N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 34. Southeast Asia N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 35. India N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 36. Australia & New Zealand N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 37. Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 38. Latin America N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Country (2021–2032)
 Figure 39. Mexico N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 40. Brazil N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 41. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 42. Middle East & Africa N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Share by Country (2021–2032)
 Figure 43. Israel N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 44. Saudi Arabia N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 45. UAE N-Acetylglutamate Synthetase Deficiency (NAGSD) Market Size YoY Growth (US$ Million), 2021–2032
 Figure 46. Recordati Rare Diseases Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 47. Grand Pharmaceutical Group Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 48. Sovereign Medical Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 49. Lee's Pharmaceuticals Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 50. Medunik Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 51. Acer Therapeutics Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 52. Sigmapharm Laboratories Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 53. Amgen Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 54. Immedica Revenue Growth Rate in N-Acetylglutamate Synthetase Deficiency (NAGSD) Business (2021–2026)
 Figure 55. Bottom-up and Top-down Approaches for This Report
 Figure 56. Data Triangulation
 Figure 57. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic

$2900

Single User License
Electronic

$4350

Multi User License
Electronic

$5800

Enterprise License
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

Global Urea Cycle Disorder UCD Drugs Market Research Report 2024
Urea Cycle Disorders UCD Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Urea Cycle Disorder Agent Market Research Report 2024
Global Argininemia Drugs Market Insights Forecast to 2030
Global Arginase Deficiency Drugs Market Insights Forecast to 2030
Global Arginase Deficiency Therapeutics Market Insights Forecast to 2030
Global Arginase Deficiency Treatment Market Insights Forecast to 2030
Inherited Metabolic Disorder Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Argininemia Treatment Market Insights Forecast to 2030
Adenosine Deaminase Deficiency Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Ornithine Transcarbamylase Deficiency Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adenosine Deaminase Deficiency Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adenosine Deaminase Deficiency Therapeutic Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Adenosine Deaminase Deficiency Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Biotinidase Deficiency Market Research Report 2024
Global Pompe Disease Treatment Market Research Report 2024
Global Peptide Based Metabolic Disorders Therapeutics Market Research Report 2024
Congenital Adrenal Hyperplasia CAH Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Alpha Antitrypsin Deficiency Treatment Market Research Report 2025
Global Acute Hyperammonemia Treatment Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions